Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Stage IV Non-Small Cell Lung Cancer AJCC v7Metastatic Malignant Neoplasm in the Brain
- Interventions
- Procedure: Cognitive AssessmentOther: Laboratory Biomarker AnalysisRadiation: Whole-Brain RadiotherapyRadiation: Stereotactic Radiosurgery
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT02696993
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer
Phase 2
Terminated
- Conditions
- Metastatic Urothelial Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT02693717
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Phase 2
Completed
- Conditions
- Invasive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7
- Interventions
- Procedure: Axillary Lymph Node DissectionOther: Laboratory Biomarker AnalysisProcedure: Lymph Node BiopsyProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT02689427
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
πΊπΈMD Anderson West Houston, Houston, Texas, United States
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
Phase 2
Active, not recruiting
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 155
- Registration Number
- NCT02689440
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Evaluation of Satisfaction With Quality of Care on the Palliative Care Unit
Completed
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
- Interventions
- Other: Survey Administration
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT02686411
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
Phase 2
Completed
- Conditions
- Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT02684162
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
Phase 2
Completed
- Conditions
- Stage IIIC Uterine Corpus Cancer AJCC v7Stage III Uterine Corpus Cancer AJCC v7Recurrent Endometrial Endometrioid AdenocarcinomaStage IIIA Uterine Corpus Cancer AJCC v7Stage IVA Uterine Corpus Cancer AJCC v7Stage IVB Uterine Corpus Cancer AJCC v7Recurrent Uterine Corpus CarcinomaStage IIIB Uterine Corpus Cancer AJCC v7Stage IV Uterine Corpus Cancer AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT02684227
- Locations
- πΊπΈ
MD Anderson League City, Nassau Bay, Texas, United States
πΊπΈMD Anderson in Katy, Houston, Texas, United States
πΊπΈMD Anderson in Sugar Land, Sugar Land, Texas, United States
Autologous Fat Grafting Techniques in Patients Undergoing Reconstructive Surgery
Completed
- Conditions
- Health Status Unknown
- Interventions
- Procedure: Autologous Fat GraftProcedure: Reconstructive Surgery
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT02677012
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v6 and v7Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT02677038
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Phase 1
Active, not recruiting
- Conditions
- Advanced CancersMelanoma
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT02668770
- Locations
- πΊπΈ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Β© Copyright 2025. All Rights Reserved by MedPath